Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

NYU grants Medco option to license adenosine A2 agonists

June 16, 1997

Cellegy discovers compounds that modulate topical inflammatory and allergic responses

June 16, 1997

Favorable preclinical results with REPEL-CV for cardiovascular surgery

June 13, 1997

Merck & Co. continues to develop 5alpha-reductase inhibitors

June 11, 1997

Inhibitors of 5alpha-reductase prepared by Merck & Co.

June 10, 1997

Preparation and use of 5alpha-reductase type 1 inhibitors described by Merck & Co.

June 6, 1997

Penederm receives SBIR grant for research on vitamin D derivative

June 5, 1997

Bristol-Myers Squibb selects diacid for development as antipsoriatic

June 4, 1997

ProCyte launches GraftCyte products

May 28, 1997

Dusa reports progress in phase III trial of Levulan PDT

May 23, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.